1998 Cumulative Table of Contents
Psychopharmacology Bulletin
Vol. 34, No. 1—1998

1997 NCDEU Selected Proceedings—Part II

1 **Editor's Note**—*Matthew V. Rudorfer*

ASSESSMENT MEASURES

3 Psychiatric Research Interview for Substance and Mental Disorders: Phenomenologically Based Diagnosis in Patients Who Abuse Alcohol or Drugs—*Deborah Hasin, Kristin Trautman, and Jean Endicott*

9 Computerized Self-Assessment of Psychosis Severity Questionnaire [COSAPSQ] in Schizophrenia: Preliminary Results—*Robert G. Stern, Ronald Fudge, Cecile E. Sison, Edward R. Allan, James Crichton, and Miklos Losonczy*

CLINICAL TRIAL METHODOLOGY

13 Developing and Comparing Treatment Strategies: An Annotated Portfolio of Designs—*Philip W. Lavori and Ree Dawson*

19 The Problem of Measurement Error in Multisite Clinical Trials—*Mark A. Demitrack, Doug Faries, John M. Herrera, David J. DeBrota, and William Z. Potter*

25 Adjusting Sample Size for Anticipated Dropouts in Clinical Trials—*John E. Overall, Ghassan Shobaki, C. Shivakumar, and Joseph Steele*

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

35 Should We Use Antidepressant Medications for Children and Adolescents With Depressive Disorders?—*Boris Birmaher*

41 Aggression Classification and Treatment Response—*Richard P. Malone, David S. Bennett, James F. Luebbert, Amy B. Rowan, Krista A. Biesecker, Bridget L. Blaney, and Mary Anne Delaney*

47 Reliability and Validity of the SKAMP Rating Scale in a Laboratory School Setting—*Sharon B. Wigal, Suneel Gupta, Diane Guinta, and James M. Swanson*

55 Objective and Subjective Measures of the Pharmacodynamic Effects of Adderall® in the Treatment of Children With ADHD in a Controlled Laboratory Classroom Setting—*James Swanson, Sharon Wigal, Larry Greenhill, Ronald Browne, Bruce Waslick, Marc Lerner, Lillie Williams, Dan Flynn, Dave Agler, Kenton L. Crowley, Erick Fineberg, Roland Regino, Martin Baren, and Dennis Cantwell*

PSYCHOTIC DISORDERS

61 Long-Term Efficacy and Safety Comparison of Sertindole and Haloperidol in the Treatment of Schizophrenia—*David G. Daniel, Patricia Wozniak, Randall J. Mack, Bruce G. McCarthy, and the Sertindole Study Group*

71 The Relationship Between Negative Symptoms of Schizophrenia and Extrapyramidal Side Effects With Haloperidol and Olanzapine—*Edward R. Allan, Cecile E. Sison, Murray Alpert, Benedict Connolly, and James Crichton*

75 Risperidone: Clinical Outcome Predictors and Cost-Effectiveness in a Naturalistic Setting—*Patrick R. Finley, Barbara R. Sommer, Joseph L. Corbitt, Gregory H. Brunson, and Bert L. Lum*

83 The Effects of Risperidone and Olanzapine on the Indications for Clozapine—*Rohan Ganguli and Jaspreet S. Brar*

89 Clozapine Reduces Rehospitalization Among Schizophrenia Patients—*Simcha Pollack, Margaret G. Woerner, Alfreda Howard, Robert B. Fireworker, and John M. Kane*

93 Initial Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CI–1007 in Patients With Schizophrenia—*John R. Sramek, Michael A. Eldon, Edward L. Posvar, Meihua R. Feng, Stanford S. Jhee, Jameel Hourani, Allen J. Sedman, and Neal R. Cutler*

101 Spontaneous Brain Magnetic Activity in Schizophrenia Patients Treated With Aripiprazole—*Jose M. Cañive, Jeffrey D. Lewine, James C. Edgar, John T. Davis, Gregory A. Miller, Fernando Torres, and Vicente B. Tuason*

ALCOHOL AND SUBSTANCE ABUSE

107 Pharmacologic Treatment of Alcoholics With Collateral Depression: Issues and Future Directions—*Raye Z. Litten and John P. Allen*

111 Naltrexone Utility in Depressed Alcoholics—*Ihsan M. Salloum, Jack R. Cornelius, Michael E. Thase, Dennis C. Daley, Levent Kirisci, and Crystal Spotts*

117 Fluoxetine Versus Placebo in Depressed Alcoholic Cocaine Abusers—*Jack R. Cornelius, Ihsan M. Salloum, Michael E. Thase, Roger F. Haskett, Dennis C. Daley, Amy Jones-Barlock, Curtis Upsher, and James R. Perel*

Vol. 34, No. 2—1998

ANXIETY DISORDERS: ADVANCES IN ASSESSMENT AND TREATMENT

123 **Editor's Note**—*Matthew V. Rudorfer*

Research in Late-Life Anxiety

127 Summary of a National Institute of Mental Health Workshop on Late-Life Anxiety—*Jane L. Pearson*

139 The Acute and Chronic Performance Effects of Alprazolam and Lorazepam in the Elderly: Relationship to Duration of Treatment and Self-Rated Sedation—*Nunzio Pomara, Hla Tun, Dan DaSilva, Raymundo Hernando, Dennis Deptula, and David J. Greenblatt*

Assessment Measures in Anxiety Disorders Research

155 Assessment Issues in Treatment Research of Pediatric Anxiety Disorders: What Is Working, What Is Not Working, What Is Missing, and What Needs Improvement—*Laurence L. Greenhill, Daniel Pine, John March, Boris Birmaher, and Mark Riddle*

165 Changes on the Temperament and Character Inventory After Paroxetine Treatment in Volunteers With Generalized Anxiety Disorder—*Christer Allgulander, C. Robert Cloninger, Thomas R. Pryzbeck, and Lena Brandt*

Pharmacotherapy Studies in Panic Disorder

Symposium: The Efficacy of New Pharmacologic Treatments for Panic Disorder

167 The Efficacy of New Pharmacological Treatments for Panic Disorder: Evaluating the Trials—*Mark Hyman Rapaport and Jonathan Davidson*

169 Pivotal Studies of Clonazepam in Panic Disorder—*Jonathan R.T. Davidson and Georges Moroz*

175 Efficacy Studies of Paroxetine in Panic Disorder—*R. Bruce Lydiard, Martin Steiner, Daniel Burnham, and Ivan Gergel*

183 Methodologies and Outcomes From the Sertraline Multicenter Flexible-Dose Trials—*Mark Hyman Rapaport, Robert M. Wolkow, and Cathryn M. Clary*

191 Efficacy Studies of Alprazolam in Panic Disorder—*David A. Spiegel*

197 Commentary: The Treatment of Panic—*Donald F. Klein*

Clinical Issues in Medication Trials

199 Long-Term Experience With Clonazepam in Patients With a Primary Diagnosis of Panic Disorder—*John J. Worthington III, Mark H. Pollack, Michael W. Otto, Renee Y.S. McLean, Georges Moroz, and Jerrold F. Rosenbaum*

207 Low-Dose Venlafaxine Treatment in Panic Disorder—*Laszlo A. Papp, Smit S. Sinha, Jose M. Martinez, Jeremy D. Coplan, Jess Amchin, and Jack M. Gorman*

211 Effect of Venlafaxine on the Pharmacokinetics of Alprazolam—*Jess Amchin, William Zarycranski, Karen P. Taylor, Dominick Albano, and Patricia M. Klockowski*

Beyond Panic: Medication Effects in Anxiety Disorders

221 A Controlled Trial of Venlafaxine in Trichotillomania: Interim Phase I Results—*Philip T. Ninan, Bettina Knight, Lori Kirk, Barbara O. Rothbaum, Jeffrey Kelsey, and Charles B. Nemeroff*

225 An Open-Label Pilot Study of Fluvoxamine for Mixed Anxiety-Depression—*Carl Houck*

229 Interclass Drug Effects and Changes in Regional Brain Glucose Metabolism—*Malcolm Cooper, John Metz, Harriet de Wit, Edwin Cook, Jonathan Lorenz, and Terry Brown*

Vol. 34, No. 3—1998

Women's Mental Health Research International Psychopharmacology Algorithm Project—Electronic Conference

233 **Editor's Note**—*Matthew V. Rudorfer*

236 **Note to Subscribers**

WOMEN'S MENTAL HEALTH RESEARCH

237 Women's Mental Health Research—What Is the Need?—*Mary C. Blehar and Matthew V. Rudorfer*

239 Women With Bipolar Disorder: Findings From the NIMH Genetics Initiative Sample—*Mary C. Blehar, J. Raymond DePaulo Jr., Elliot S. Gershon, Theodore Reich, Sylvia G. Simpson, and John I. Nurnberger Jr.*

Assessment of Women's Mental Health

245 Preface—*Uriel Halbreich*

247 Evaluation of Women's Mental Health: Delineation of the Field, and Needs and Steps Toward a Consensus—*Uriel Halbreich*

251 Clinically Relevant Basic Science Studies of Gender Differences and Sex Hormone Effects—*Bruce S. McEwen, S.E. Alves, K. Bulloch, and N.G. Weiland*

Broad Diagnostic Overviews

261 Assessing Unipolar Mood Disorders in Women—*Kimberly A. Yonkers*

267 Recognizing Eating Disorders in Women—*Regina C. Casper*

271 The Evaluation of Women With Schizophrenia—*Carla M. Canuso, Jill M. Goldstein, and Alan I. Green*

279 Diagnostic Evaluation of Alcohol and Drug Abuse Problems in Women—*Jack H. Mendelson and Nancy K. Mello*

Further Needs in Clinical Assessment

283 Comprehensive Evaluation of Current and Past Mental Health in Women—*Jean Endicott*

289 Hormone Measures in Reproductive Endocrine-Related Mood Disorders: Diagnostic Issues—*David R. Rubinow, Peter J. Schmidt, and Catherine A. Roca*

291 Premenstrual Syndromes—*Ellen W. Freeman and Uriel Halbreich*

297 Evaluation of Mental Health and Depression During Pregnancy: Position Paper—*Victoria Hendrick, Lori Altshuler, Lee Cohen, and Zachary Stowe*

301 Perinatal Mood Disorders: Position Paper—*Meir Steiner*

307 Women and Infertility—*Miriam Rosenthal*

309 Clinical Evaluation in Studies of Perimenopausal Women: Position Paper—*Peter J. Schmidt, Catherine A. Roca, and David R. Rubinow*

313 Mood Disorders and the Reproductive Cycle: Affective Disorders During the Menopause and Premenstrual Dysphoric Disorder—*Patricia Haynes and Barbara L. Parry*

319 Augmentation of Antidepressants by Estrogen—*Stephen M. Stahl*

323 Cognitive Assessment for Postmenopausal Women and General Assessment of Their Mental Health—*Barbara B. Sherwin*

327 Future Directions For Studies of Women's Mental Health—*Uriel Halbreich*

Marcé Society Reports

333 Mental Disorders Associated With Childbearing: Report of the Biennial Meeting of the Marcé Society—*Scott Stuart, Michael W. O'Hara, and Mary C. Blehar*

339 The Course and Management of Bipolar Disorder During Pregnancy—*Adele C. Viguera and Lee S. Cohen*

INTERNATIONAL PSYCHOPHARMACOLOGY ALGORITHM PROJECT—ELECTRONIC CONFERENCE

347 Introduction—*Kenneth O. Jobson and Alan Schatzberg*

349 A New Algorithm for Treating Schizophrenia—*Rowland Pearsall, Ira D. Glick, David Pickar, Trisha Suppes, Johannes Tauscher, and Kenneth O. Jobson*

355 Developing Treatment Algorithms for Unipolar Depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP)—*Madhukar H. Trivedi, Charles DeBattista, Jan Fawcett, Craig Nelson, David N. Osser, Dan Stein, and Kenneth Jobson*

361 Observer's Report—*Dean S. Hartley III* (Rapporteur)

369 Synthesis Committee Report—*Kenneth O. Jobson,* (Rapporteur), *Alan Schatzberg, Jan Fawcett, Craig Nelson, and Dan Stein* (Members)

371 Appendix—International Psychopharmacology Algorithm Project World Wide Web Conference Participants

CURRENT TOPICS IN CLINICAL PSYCHOPHARMACOLOGY

373 Economic Outcomes of Antipsychotic Agents in a Medicaid Population: Traditional Agents vs. Risperidone—*Brian S. Nightengale, John M. Crumly, Jason Liao, Bryan J. Lawrence, and Elgene W. Jacobs*

383 Effect of Venlafaxine on the Pharmacokinetics of Terfenadine—*Jess Amchin, William Zarycranski, Karen P. Taylor, Dominick Albano, and Patricia M. Klockowski*

391 The Pharmacological Effects of *Ginkgo Biloba*, a Plant Extract, On the Brain of Dementia Patients in Comparison With Tacrine—*Turan M. Itil, Emin Eralp, Islah Ahmed, Aileen Kunitz, and Kurt Z. Itil*

Vol. 34, No. 4—1998

History of the *Psychopharmacology Bulletin* / Evidence Report on Treatment of Depression—Newer Pharmacotherapies

399 **Editor's Note**—*Matthew V. Rudorfer*

405 **A Brief History of the *Psychopharmacology Bulletin***—*Robert F. Prien*

409 **Evidence Report:** Treatment of Depression–Newer Pharmacotherapies—*Cynthia D. Mulrow, John W. Williams, Jr., Madhukar Trivedi, Elaine Chiquette, Christine Aguilar, John E. Cornell, Robert Badgett, Polly Hitchcock Noël, Valerie Lawrence, Shuko Lee, Michael Luther, Gilbert Ramirez, W. Scott Richardson, and Karen Stamm*

797 High Frequency of CYP2D6 Poor and "Intermediate" Metabolizers in Black Populations: A Review and Preliminary Data—*L. DiAnne Bradford, Andrea Gaedigk, and J. Steven Leeder*

805 A Strategy to Evaluate a Covariate by Group Interaction in an Analysis of Covariance—*Andrew C. Leon, Laura Portera, Kira Lowell, and David Rheinheimer*

811 A Bridging Study of Fananserin in Schizophrenic Patients—*John J. Sramek, Stéphane Kirkesseli, Anne Paccaly-Moulin, Jill Davidson, Stanford S. Jhee, Jameel Hourani, Dorothée Sémiond, and Neal R. Cutler*

819 Olanzapine Therapy in Elderly Patients With Schizophrenia—*Martha Sajatovic, Dalia Perez, Debra Brescan, and Luis F. Ramirez*

825 Evaluation of Individual Subjects in the Analog Classroom Setting: I. Examples of Graphical and Statistical Procedures for Within-Subject Ranking of Responses to Different Delivery Patterns of Methylphenidate—*James M. Swanson, Sharon B. Wigal, Dan Udrea, Marc Lerner, Dave Agler, Dan Flynn, Erick Fineberg, Mark Davies, David Kardatzke, Anshumala Ram, and Suneel Gupta*

833 Evaluation of Individual Subjects in the Analog Classroom Setting: II. Effects of Dose of Amphetamine (Adderall®)—*Sharon B. Wigal, James M. Swanson, Larry Greenhill, Bruce Waslick, Dennis Cantwell, Walter Clevenger, Mark Davies, Mark Lerner, Roland Regino, Erick Fineberg, Martin Baren, and Ronald Browne*

839 **1998 Cumulative Table of Contents**

845 **1998 Cumulative Author Index**

851 **1998 Cumulative Keyword Index**